340B Fraud and Overcharging: Who Got the Discount, and Who Paid Too Much?

340B fraud can involve duplicate Medicaid discounts, drugs diverted to people outside a covered entity’s patient population, or overcharging tied to discounted drugs. The evidence sits in different places: a manufacturer’s price calculation, a pharmacy’s eligibility decision, or a hospital’s reimbursement claim. If you work with those records, you may see exactly where the discount went wrong.

How the 340B Discount Works

The 340B Drug Pricing Program gives eligible hospitals and clinics access to discounted outpatient drugs. These purchasers, called covered entities, include federally qualified health centers, certain hospitals serving low-income patients, and other qualifying providers. Manufacturers enter pricing agreements with the government, and participation is tied to Medicaid coverage of their drugs.

The 340B provisions of the Public Health Service Act cap what manufacturers can charge covered entities. The ceiling price starts with the preceding quarter’s average manufacturer price, then subtracts the Medicaid unit rebate amount. The manufacturer calculates the ceiling for each National Drug Code every quarter under the ceiling-price regulation. That makes the inputs consequential: a price-reporting decision made inside a manufacturer can change what safety-net providers pay.

The purchase price and the reimbursement are separate transactions. A covered entity can buy at the discounted price and receive a higher payment from Medicare or private insurance. The difference helps fund the provider’s operations.

A Government Accountability Office analysis published in 2015, using 2008 and 2012 data, found higher Medicare Part B drug spending per beneficiary at participating disproportionate-share hospitals than at other hospitals, including for oncology drugs. The differences did not appear to be explained by the hospital characteristics or patients’ health status GAO examined. The report identified an incentive to prescribe more drugs or more expensive drugs under the payment arrangements it studied.

The Pharmacy May Dispense Before the Discount Is Assigned

A contract pharmacy can dispense a drug before the prescription is classified as eligible for the covered entity’s discount. Under the product-replenishment model, the pharmacy can fill prescriptions from inventory that mixes discounted and nondiscounted drugs. The covered entity, pharmacy or third-party administrator then identifies eligible prescriptions and orders discounted stock to replenish them.

The eligibility decision can therefore happen after the patient has left. A pharmacy employee sees the dispense. An administrator sees the information used to classify it. A purchasing team sees the replenishment order. Connecting those records shows which prescription earned which discount.

The Government Accountability Office’s 2018 contract-pharmacy report also describes the money flow. The pharmacy collects patient and insurer payments. The pharmacy and administrator typically deduct their negotiated fees, then send the balance to the covered entity. The Health Resources and Services Administration’s guidance had expanded from allowing one outside pharmacy for an entity without an in-house pharmacy to allowing multiple contract pharmacies in 2010. The arrangement puts both eligibility decisions and money in the hands of several participants.

Duplicate Medicaid Discounts: The Manufacturer Pays Twice

A duplicate Medicaid discount occurs when the same drug receives a 340B discount and also generates a Medicaid rebate from the manufacturer. The manufacturer supplies the discount at purchase and pays again through the state’s rebate request. The key connection is the same drug unit appearing in both streams.

Medicaid pays through different channels. Under fee-for-service, the state pays providers directly. Under managed care, the state contracts with a health plan to arrange care. Medicaid rebates extend to drugs dispensed through managed care as well as fee-for-service. That distinction matters when the pharmacy’s claims data and the state’s rebate data are compared.

The Government Accountability Office found in 2018 that HRSA’s audits assessed the potential for duplicate discounts in fee-for-service but did not review covered entities’ processes for preventing them in managed care. Managed care already accounted for most Medicaid prescriptions. The audit review concentrated on the smaller channel.

For an insider, the evidence question is concrete: how did the system identify a prescription as 340B, and how was that identification carried into Medicaid rebate processing? The Medicaid Exclusion File identifies covered-entity provider numbers for fee-for-service duplicate-discount prevention. Managed-care claims need their own examination. We connect the dispensing and replenishment records to the payer channel and the rebate treatment, including what the entity told the state.

What Happened After the Audit?

The Health Resources and Services Administration generally relied on the covered entity’s assurance that it had corrected the problem and completed repayments, the 2018 report found. One entity had participated in the program for three years but reviewed only five months of claims to assess the extent of diversion. The review period determined how much of the problem the correction could reach.

The entity chose the review period, identified the affected manufacturers and contacted them. A manufacturer left out of that review could be left out of the repayment discussion too. That makes the internal review and the repayment records useful evidence alongside the original transactions.

The agency’s published audit process now describes closure after an entity confirms that repayments and its corrective action plan are complete. It also allows the agency to demand additional documentation and conduct another audit. An employee who knows what the review covered can help us examine the correction against the underlying claims.

Patient Diversion: Who Received the Discounted Drug?

340B patient diversion concerns a discounted drug transferred to someone who is not a patient of the covered entity. The relationship between the person receiving the drug and the entity claiming the discount is the central issue.

The statute uses the word patient without defining it. The Health Resources and Services Administration’s patient-definition guidance addresses the entity’s healthcare records, the professional providing care and the entity’s continuing responsibility for that care. For certain grantees, the service must also fit the services for which they qualify. These are the details a pharmacy or administrator’s eligibility decision must be examined against.

The agency’s patient-definition resources, reviewed in January 2024, say its guidelines continue to guide audits. The distinction between those guidelines and the statute has nevertheless changed enforcement. The Government Accountability Office reported that HRSA stopped issuing findings based solely on noncompliance with guidance.

Of the fiscal-year 2019 audits finalized by September 2020, GAO identified 36 instances that would previously have produced findings but did not under the changed approach. The agency changed what it counted. A falling finding count could now reflect that change rather than better conduct.

The operational question remains close to the prescription. What care did the patient receive? Which entity maintained the health care records and responsibility for the care? What information did the administrator use to assign the discount? We work through those questions with insiders who know how the prescriptions were classified. A computer’s eligibility flag has a decision behind it.

340B Overcharging Can Start at Either End

340B overcharging can start at either end of the transaction. A manufacturer can charge a covered entity above the applicable ceiling price. A covered entity can also overbill a government payer by claiming a higher drug cost than the reimbursement rules allow. The first comparison is the manufacturer’s charge against its ceiling. The second is the provider’s claim against the payment rule.

Manufacturer Ceiling-Price Overcharges

A manufacturer can inflate a ceiling by misreporting the prices that feed the calculation. Best Price affects the Medicaid rebate, and that rebate affects the 340B ceiling. An omitted discount can leave Medicaid with too little rebate and a covered entity paying too much for the same product.

Aventis agreed to a $95.5 million settlement announced in May 2009 over alleged Best Price misreporting. The Justice Department described private-label arrangements with Kaiser Permanente for nasal sprays. According to the government, Aventis repackaged its drugs under a different label to avoid reporting a new Best Price and the larger Medicaid rebates it would trigger.

The alleged consequence reached beyond Medicaid. More than $6 million of the settlement went to Public Health Service entities the government said had paid inflated prices. In the government’s account, the label changed. The drugs did not.

For a manufacturer pricing analyst, the important documents can be the discount agreement, the treatment of that agreement in Best Price, and the resulting rebate and ceiling-price calculations. For a covered-entity buyer, the comparison begins with the invoice and the applicable ceiling. The Health Resources and Services Administration’s manufacturer audit process examines sales transactions and ceiling-price compliance, with refunds to covered entities for overcharges.

Pomona Valley and the Cost Claimed to Medicaid

Pomona Valley Hospital Medical Center illustrates the reimbursement side. In a resolution announced in February 2024, the government alleged that the hospital had billed higher usual-and-customary costs instead of the lower actual acquisition costs required for the discounted drugs. The alleged billing ran from December 2016 through September 2021.

The hospital agreed to pay $873,730 to the United States and $1,225,954 to California. Its own internal audit led to voluntary disclosures. The allegation turned on what Pomona paid for the drugs against what it claimed from Medicaid.

For someone in hospital pharmacy purchasing or reimbursement, that is a familiar divide. Purchasing records show the discounted acquisition cost. Billing records show the amount submitted for payment. The reimbursement rule determines which cost the claim should carry. We examine those records together to see how the higher amount reached the payer and who understood the difference.

When 340B Conduct Becomes a False Claims Act Case

A 340B False Claims Act case follows the false price or claim to the government payment. The Aventis settlement concerned alleged price misreporting that reduced Medicaid rebates. Pomona’s settlement concerned alleged Medicaid billing above the required acquisition cost. In both, public healthcare money was at stake.

A whistleblower’s knowledge can explain the decisions behind the numbers. A price analyst may understand why a discount was omitted from a calculation. A hospital billing employee may know why the amount claimed exceeded acquisition cost. A pharmacy administrator may understand how the same prescription entered both the discounted inventory and Medicaid rebate streams. We connect that inside knowledge to the payment and the decisions behind it.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

What an Insider Can See

The records that matter depend on the failure. Manufacturer pricing work connects sales and discounts to reported prices. Patient records and eligibility decisions connect the person receiving care to the covered entity. Dispensing, replenishment and reimbursement records connect the drug to the discount and the payer.

The Health Resources and Services Administration’s audits examine how policies operate, including inpatient and outpatient classifications, Medicaid Exclusion File designations and sampled drug transactions. They also reach contract pharmacies. Those are working systems familiar to pharmacy, finance and compliance employees.

An insider can explain where those systems disagree and what happened when the disagreement was raised. We put that explanation beside the transactions, the internal audit and any correction or repayment. The useful story is the one that follows the drug and the money through the people who made the decisions.

When You Know Where the Discount Went Wrong

If you know how a pricing decision inflated a bill or a prescription received a discount it was not entitled to, speak to one of our whistleblower experts about how the discount went wrong. We work with you to build your strongest 340B whistleblower case around those decisions and bring in pharmaceutical whistleblower lawyers who understand drug pricing and government reimbursement. We stay beside you throughout the case, keeping the decisions you witnessed at the center of the work.